News | December 28, 2023
Elpiscience and Astellas collaborate for novel bispecific macrophage engager
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Equipped with most advanced Distributed Control System (DCS) automation technology, the facility has been set up with an investment of Rs. 200 crore
New Molecular biology lab launched, AIIA increased its work scope in form of MoUs
NRT offers 50% higher success rate in quitting smoking compared to unassisted attempts
This integrated care offering is a step forward in our vision of providing an effective continuum of care for patients
Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction
Robots make it to the healthcare conference panel, reflecting the future potential of technology
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
Subscribe To Our Newsletter & Stay Updated
